Payment overview · 2025
General Payments
$207.59
12 reported records · 7 companies
Healthcare provider profile · identity verified
Amber Rose Maruca
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · CRESSON, PA · NPI 1912435322
Verified facts
What the public records show
CMS Open Payments records show Amber Rose Maruca received $207.59 in general payments during 2025 across 12 reported records.
Exact Sciences Corporation accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.82 | 25.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.68 | 19.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.81 | 16.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.10 | 16.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.27 | 7.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.93 | 7.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.98 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $207.59 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.82 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.81 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.81 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 237 | 60 |
| Losartan Potassium | Losartan Potassium | 230 | 54 |
| Metformin Hcl | Metformin Hcl | 230 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 57 |
| Furosemide | Furosemide | 199 | 60 |
| Lisinopril | Lisinopril | 188 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 186 | 44 |
| Simvastatin | Simvastatin | 168 | 45 |
| Montelukast Sodium | Montelukast Sodium | 153 | 43 |
| Gabapentin | Gabapentin | 152 | 49 |
| Potassium Chloride | Potassium Chloride | 152 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 43 |
| Famotidine | Famotidine | 129 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 31 |
| Lorazepam | Lorazepam | 121 | 33 |
| Alprazolam | Alprazolam | 120 | 23 |
| Prednisone | Prednisone | 116 | 73 |
| Omeprazole | Omeprazole | 112 | 37 |
| Tramadol Hcl | Tramadol Hcl | 112 | 36 |
| Jardiance | Empagliflozin | 105 | 19 |
| Allopurinol | Allopurinol | 104 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 24 |
| Eliquis | Apixaban | 78 | 19 |
| Ozempic | Semaglutide | 75 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 12 |
| Sertraline Hcl | Sertraline Hcl | 73 | 25 |
| Trazodone Hcl | Trazodone Hcl | 71 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 16 |
| Synthroid | Levothyroxine Sodium | 63 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 12 |
| Cephalexin | Cephalexin | 59 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 48 |
| Alendronate Sodium | Alendronate Sodium | 58 | 15 |
| Carvedilol | Carvedilol | 56 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 12 |
| Pregabalin | Pregabalin | 56 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 14 |
| Mirtazapine | Mirtazapine | 51 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 14 |
| Warfarin Sodium | Warfarin Sodium | 49 | 12 |
| Topiramate | Topiramate | 48 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 47 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 11 |
| Celecoxib | Celecoxib | 44 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 37 |
| Meloxicam | Meloxicam | 41 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 33 |
| Glipizide Er | Glipizide | 36 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | 14 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 15 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | 11 |
| Fluconazole | Fluconazole | 27 | 19 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Nystatin | Nystatin | 21 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 14 |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $207.59 · 12 records | Exact Sciences Corporation | Cologuard Collection Kit, MOUNJARO, Ozempic, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error